The PKR activator, PACT, becomes a PKR inhibitor during HIV-1 replication

Retrovirology

Volumn 10, Issue 1, 2013, Pages

  Clerzius, Guerline ^a,b,f   Shaw, Eileen ^a,b   Daher, Aïcha ^a   Burugu, Samantha ^a,c   Gélinas, Jean François ^a,c,g   Ear, Thornin ^a,b   Sinck, Lucile ^a,b   Routy, Jean Pierre ^b,d   Mouland, Andrew J ^a,b,c   Patel, Rekha C ^e   Gatignol, Anne ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^e UNIVERSITY OF SOUTH CAROLINA   (United States)

^f MCGILL UNIVERSITY   (Canada)

^g UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Astrocytes; Eukaryotic translation initiation factor 2 (eIF2 ); Human immunodeficiency virus type 1 (HIV 1); Lymphocytes; PKR activator (PACT); Protein kinase RNA activated (PKR)

Indexed keywords

ADENOSINE DEAMINASE; ARGONAUTE 2 PROTEIN; DOUBLE STRANDED RNA; MICROSOMAL AMINOPEPTIDASE; PROTEIN KINASE R; PROTEIN KINASE R ACTIVATOR; RNA BINDING PROTEIN; SHORT HAIRPIN RNA; TAR RNA BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ASTROCYTE; CARBOXY TERMINAL SEQUENCE; CELL LINE; CELL STRESS; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOPRECIPITATION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; VIRION; VIRUS REPLICATION;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOSINE DEAMINASE; CELL LINE; EIF-2 KINASE; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA-BINDING PROTEINS; VIRUS REPLICATION;

EID: 84883652077     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-10-96     Document Type: Article

References (86)

1. Bolinger C, Boris-Lawrie K. Mechanisms employed by retroviruses to exploit host factors for translational control of a complicated proteome. Retrovirol 2009, 6:8.
2. Gatignol A. Transcription of HIV: Tat and cellular chromatin. Adv Pharmacol 2007, 55:137-159.
3. McLaren M, Marsh K, Cochrane A. Modulating HIV-1 RNA processing and utilization. Front Biosci 2008, 13:5693-5707.
4. Anderson JL, Johnson AT, Howard JL, Purcell DF. Both linear and discontinuous ribosome scanning are used for translation initiation from bicistronic human immunodeficiency virus type 1 env mRNAs. J Virol 2007, 81:4664-4676. 10.1128/JVI.01028-06, 1900145, 17329338.
5. Brasey A, Lopez-Lastra M, Ohlmann T, Beerens N, Berkhout B, Darlix JL, Sonenberg N. The leader of human immunodeficiency virus type 1 genomic RNA harbors an internal ribosome entry segment that is active during the G2/M phase of the cell cycle. J Virol 2003, 77:3939-3949. 10.1128/JVI.77.7.3939-3949.2003, 150645, 12634354.
6. Charbonneau J, Gendron K, Ferbeyre G, Brakier-Gingras L. The 5′ UTR of HIV-1 full-length mRNA and the Tat viral protein modulate the programmed -1 ribosomal frameshift that generates HIV-1 enzymes. RNA 2012, 18:519-529. 10.1261/rna.030346.111, 3285939, 22286970.
7. Bannwarth S, Gatignol A. HIV-1 TAR RNA: the target of molecular interactions between the virus and its host. Curr HIV Res 2005, 3:61-71. 10.2174/1570162052772924, 15638724.
8. Dorin D, Bonnet MC, Bannwarth S, Gatignol A, Meurs EF, Vaquero C. The TAR RNA-binding protein, TRBP, stimulates the expression of TAR-containing RNAs in vitro and in vivo independently of its ability to inhibit the dsRNA-dependent kinase PKR. J Biol Chem 2003, 278:4440-4448. 10.1074/jbc.M208954200, 12475984.
9. Dugré-Brisson S, Elvira G, Boulay K, Chatel-Chaix L, Mouland AJ, DesGroseillers L. Interaction of Staufen1 with the 5′ end of mRNA facilitates translation of these RNAs. Nucleic Acids Res 2005, 33:4797-4812. 10.1093/nar/gki794, 1193567, 16126845.
10. Gendron K, Charbonneau J, Dulude D, Heveker N, Ferbeyre G, Brakier-Gingras L. The presence of the TAR RNA structure alters the programmed -1 ribosomal frameshift efficiency of the human immunodeficiency virus type 1 (HIV-1) by modifying the rate of translation initiation. Nucleic Acids Res 2008, 36:30-40. 2248755, 17984074.
11. Chang YN, Kenan DJ, Keene JD, Gatignol A, Jeang KT. Direct interactions between autoantigen La and human immunodeficiency virus leader RNA. J Virol 1994, 68:7008-7020. 237138, 7933083.
12. Clerzius G, Gélinas JF, Daher A, Bonnet M, Meurs EF, Gatignol A. ADAR1 interacts with PKR during human immunodeficiency virus infection of lymphocytes and contributes to viral replication. J Virol 2009, 83:10119-10128. 10.1128/JVI.02457-08, 2747994, 19605474.
13. Daniels SM, Gatignol A. The multiple functions of TRBP, at the Hub of cell responses to viruses, stress, and cancer. Microbiol Mol Biol Rev 2012, 76:652-666. 10.1128/MMBR.00012-12, 3429622, 22933564.
14. Gatignol A, Buckler-White A, Berkhout B, Jeang KT. Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science 1991, 251:1597-1600. 10.1126/science.2011739, 2011739.
15. Gélinas JF, Clerzius G, Shaw E, Gatignol A. Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase. J Virol 2011, 85:8460-8466. 10.1128/JVI.00240-11, 3165853, 21490091.
16. Christensen HS, Daher A, Soye KJ, Frankel LB, Alexander MR, Lainé S, Bannwarth S, Ong CL, Chung SW, Campbell SM, Purcell DF, Gatignol A. Small interfering RNAs against the TAR RNA binding protein, TRBP, a dicer cofactor, inhibit human immunodeficiency virus type 1 long terminal repeat expression and viral production. J Virol 2007, 81:5121-5131. 10.1128/JVI.01511-06, 1900231, 17360756.
17. Clerzius G, Gélinas JF, Gatignol A. Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol 2011, 21:42-53. 10.1002/rmv.674, 21294215.
18. Daher A, Laraki G, Singh M, Melendez-Peña CE, Bannwarth S, Peters AH, Meurs EF, Braun RE, Patel RC, Gatignol A. TRBP control of PACT-induced phosphorylation of PKR is reversed by stress. Mol Cell Biol 2009, 29:254-265. 10.1128/MCB.01030-08, 2612476, 18936160.
19. Daher A, Longuet M, Dorin D, Bois F, Segeral E, Bannwarth S, Battisti PL, Purcell DF, Benarous R, Vaquero C, Meurs EF, Gatignol A. Two dimerization domains in the trans-activation response RNA-binding protein (TRBP) individually reverse the protein kinase R inhibition of HIV-1 long terminal repeat expression. J Biol Chem 2001, 276:33899-33905. 10.1074/jbc.M103584200, 11438532.
20. Singh M, Castillo D, Patel CV, Patel RC. Stress-induced phosphorylation of PACT reduces its interaction with TRBP and leads to PKR activation. Biochemistry 2011, 50:4550-4560. 10.1021/bi200104h, 21526770.
21. Dabo S, Meurs EF. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses 2012, 4:2598-2635. 10.3390/v4112598, 3509664, 23202496.
22. García MA, Gil J, Ventoso I, Guerra S, Domingo E, Rivas C, Esteban M. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev 2006, 70:1032-1060. 10.1128/MMBR.00027-06, 1698511, 17158706.
23. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, Hovanessian AG. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 1990, 62:379-390. 10.1016/0092-8674(90)90374-N, 1695551.
24. Sadler AJ, Williams BR. Structure and function of the protein kinase R. Curr Top Microbiol Immunol 2007, 316:253-292. 10.1007/978-3-540-71329-6_13, 17969452.
25. Bonnet MC, Daurat C, Ottone C, Meurs EF. The N-terminus of PKR is responsible for the activation of the NF-kappaB signaling pathway by interacting with the IKK complex. Cell Signal 2006, 18:1865-1875. 10.1016/j.cellsig.2006.02.010, 16600570.
26. Gil J, García MA, Gomez-Puertas P, Guerra S, Rullas J, Nakano H, Alcamí J, Esteban M. TRAF family proteins link PKR with NF-kappa B activation. Mol Cell Biol 2004, 24:4502-4512. 10.1128/MCB.24.10.4502-4512.2004, 400457, 15121867.
27. Adelson ME, Martinand-Mari C, Iacono KT, Muto NF, Suhadolnik RJ. Inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Eur J Biochem 1999, 264:806-815. 10.1046/j.1432-1327.1999.00661.x, 10491127.
28. Benkirane M, Neuveut C, Chun RF, Smith SM, Samuel CE, Gatignol A, Jeang KT. Oncogenic potential of TAR RNA binding protein TRBP and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO J 1997, 16:611-624. 10.1093/emboj/16.3.611, 1169664, 9034343.
29. Dimitrova DI, Yang X, Reichenbach NL, Karakasidis S, Sutton RE, Henderson EE, Rogers TJ, Suhadolnik RJ. Lentivirus-mediated transduction of PKR into CD34(+) hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny. J Interferon Cytokine Res 2005, 25:345-360. 10.1089/jir.2005.25.345, 15957958.
30. Muto NF, Martinand-Mari C, Adelson ME, Suhadolnik RJ. Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct. J Virol 1999, 73:9021-9028. 112934, 10516008.
31. Cai R, Carpick B, Chun RF, Jeang KT, Williams BR. HIV-I TAT inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms. Arch Biochem Biophys 2000, 373:361-367. 10.1006/abbi.1999.1583, 10620360.
32. García MA, Meurs EF, Esteban M. The dsRNA protein kinase PKR: virus and cell control. Biochimie 2007, 89:799-811. 10.1016/j.biochi.2007.03.001, 17451862.
33. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008, 8:559-568. 10.1038/nri2314, 2522268, 18575461.
34. Goodman AG, Smith JA, Balachandran S, Perwitasari O, Proll SC, Thomas MJ, Korth MJ, Barber GN, Schiff LA, Katze MG. The cellular protein P58IPK regulates influenza virus mRNA translation and replication through a PKR-mediated mechanism. J Virol 2007, 81:2221-2230. 10.1128/JVI.02151-06, 1865913, 17166899.
35. Goodman AG, Tanner BC, Chang ST, Esteban M, Katze MG. Virus infection rapidly activates the P58(IPK) pathway, delaying peak kinase activation to enhance viral replication. Virology 2011, 417:27-36. 10.1016/j.virol.2011.04.020, 3152592, 21612809.
36. Li Z, Okonski KM, Samuel CE. Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus. J Virol 2012, 86:3787-3794. 10.1128/JVI.06307-11, 3302501, 22278222.
37. Mittelstadt M, Frump A, Khuu T, Fowlkes V, Handy I, Patel CV, Patel RC. Interaction of human tRNA-dihydrouridine synthase-2 with interferon-induced protein kinase PKR. Nucleic Acids Res 2008, 36:998-1008. 2241914, 18096616.
38. Nie Y, Hammond GL, Yang JH. Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection. J Virol 2007, 81:917-923. 10.1128/JVI.01527-06, 1797455, 17079286.
39. Sanghvi VR, Steel LF. The cellular TAR RNA binding protein, TRBP, promotes HIV-1 replication primarily by inhibiting the activation of double-stranded RNA-dependent kinase PKR. J Virol 2011, 85:12614-12621. 10.1128/JVI.05240-11, 3209364, 21937648.
40. Toth AM, Devaux P, Cattaneo R, Samuel CE. Protein kinase PKR mediates the apoptosis induction and growth restriction phenotypes of C protein-deficient measles virus. J Virol 2009, 83:961-968. 10.1128/JVI.01669-08, 2612345, 19004947.
41. Fasciano S, Hutchins B, Handy I, Patel RC. Identification of the heparin-binding domains of the interferon-induced protein kinase, PKR. FEBS J 2005, 272:1425-1439. 10.1111/j.1742-4658.2005.04575.x, 15752359.
42. Ito T, Yang M, May WS. RAX, a cellular activator for double-stranded RNA-dependent protein kinase during stress signaling. J Biol Chem 1999, 274:15427-15432. 10.1074/jbc.274.22.15427, 10336432.
43. Pataer A, Vorburger SA, Chada S, Balachandran S, Barber GN, Roth JA, Hunt KK, Swisher SG. Melanoma differentiation-associated gene-7 protein physically associates with the double-stranded RNA-activated protein kinase PKR. Mol Ther 2005, 11:717-723. 10.1016/j.ymthe.2005.01.018, 15851010.
44. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J 1998, 17:4379-4390. 10.1093/emboj/17.15.4379, 1170771, 9687506.
45. Roh V, Laemmle A, Von Holzen U, Stroka D, Dufour JF, Hunt KK, Candinas D, Vorburger SA. Dual induction of PKR with E2F-1 and IFN-alpha to enhance gene therapy against hepatocellular carcinoma. Cancer Gene Ther 2008, 15:636-644. 10.1038/cgt.2008.34, 18535617.
46. Zhang HM, Ye X, Su Y, Yuan J, Liu Z, Stein DA, Yang D. Coxsackievirus B3 infection activates the unfolded protein response and induces apoptosis through downregulation of p58IPK and activation of CHOP and SREBP1. J Virol 2010, 84:8446-8459. 10.1128/JVI.01416-09, 2918999, 20554776.
47. Bannwarth S, Lainé S, Daher A, Grandvaux N, Clerzius G, LeBlanc AC, Hiscott J, Gatignol A. Cell-specific regulation of TRBP1 promoter by NF-Y transcription factor in lymphocytes and astrocytes. J Mol Biol 2006, 355:898-910. 10.1016/j.jmb.2005.11.026, 16343534.
48. Bannwarth S, Talakoub L, Letourneur F, Duarte M, Purcell DF, Hiscott J, Gatignol A. Organization of the human tarbp2 gene reveals two promoters that are repressed in an astrocytic cell line. J Biol Chem 2001, 276:48803-48813. 10.1074/jbc.M104645200, 11641396.
49. Ong CL, Thorpe JC, Gorry PR, Bannwarth S, Jaworowski A, Howard JL, Chung S, Campbell S, Christensen HS, Clerzius G, Mouland AJ, Gatignol A, Purcell DF. Low TRBP levels support an innate human immunodeficiency virus type 1 resistance in astrocytes by enhancing the PKR antiviral response. J Virol 2005, 79:12763-12772. 10.1128/JVI.79.20.12763-12772.2005, 1235869, 16188979.
50. Doria M, Neri F, Gallo A, Farace MG, Michienzi A. Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res 2009, 37:5848-5858. 10.1093/nar/gkp604, 2761272, 19651874.
51. Doria M, Tomaselli S, Neri F, Ciafrè SA, Farace MG, Michienzi A, Gallo A. ADAR2 editing enzyme is a novel human immunodeficiency virus-1 proviral factor. J Gen Virol 2011, 92:1228-1232. 10.1099/vir.0.028043-0, 21289159.
52. Patel CV, Handy I, Goldsmith T, Patel RC. PACT, a stress-modulated cellular activator of interferon-induced double-stranded RNA-activated protein kinase, PKR. J Biol Chem 2000, 275:37993-37998. 10.1074/jbc.M004762200, 10988289.
53. Bennett RL, Blalock WL, Abtahi DM, Pan Y, Moyer SA, May WS. RAX, the PKR activator, sensitizes cells to inflammatory cytokines, serum withdrawal, chemotherapy, and viral infection. Blood 2006, 108:821-829. 10.1182/blood-2005-11-006817, 1617065, 16861340.
54. Bennett RL, Blalock WL, May WS. Serine 18 phosphorylation of RAX, the PKR activator, is required for PKR activation and consequent translation inhibition. J Biol Chem 2004, 279:42687-42693. 10.1074/jbc.M403321200, 15299031.
55. Laraki G, Clerzius G, Daher A, Melendez-Peña C, Daniels S, Gatignol A. Interactions between the double-stranded RNA-binding proteins TRBP and PACT define the Medipal domain that mediates protein-protein interactions. RNA Biol 2008, 5:92-103. 10.4161/rna.5.2.6069, 18421256.
56. Singh M, Patel RC. Increased interaction between PACT molecules in response to stress signals is required for PKR activation. J Cell Biochem 2012, 113:2754-2764. 10.1002/jcb.24152, 22473766.
57. Gupta V, Huang X, Patel RC. The carboxy-terminal, M3 motifs of PACT and TRBP have opposite effects on PKR activity. Virology 2003, 315:283-291. 10.1016/S0042-6822(03)00589-0, 14585331.
58. Huang X, Hutchins B, Patel RC. The C-terminal, third conserved motif of the protein activator PACT plays an essential role in the activation of double-stranded-RNA-dependent protein kinase (PKR). Biochem J 2002, 366:175-186. 1222748, 11985496.
59. Peters GA, Hartmann R, Qin J, Sen GC. Modular structure of PACT: distinct domains for binding and activating PKR. Mol Cell Biol 2001, 21:1908-1920. 10.1128/MCB.21.6.1908-1920.2001, 86773, 11238927.
60. Casey JL, Bergmann KF, Brown TL, Gerin JL. Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci USA 1992, 89:7149-7153. 10.1073/pnas.89.15.7149, 49663, 1496009.
61. Peters GA, Li S, Sen GC. Phosphorylation of specific serine residues in the PKR activation domain of PACT is essential for its ability to mediate apoptosis. J Biol Chem 2006, 281:35129-35136. 10.1074/jbc.M607714200, 16982605.
62. Hosmalin A, Lebon P. Type I interferon production in HIV-infected patients. J Leukoc Biol 2006, 80:984-993. 10.1189/jlb.0306154, 16916960.
63. Diop OM, Ploquin MJ, Mortara L, Faye A, Jacquelin B, Kunkel D, Lebon P, Butor C, Hosmalin A, Barré-Sinoussi F, Müller-Trutwin MC. Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol 2008, 82:5145-5152. 10.1128/JVI.02433-07, 2395206, 18385227.
64. Herbeuval JP, Shearer GM. HIV-1 immunopathogenesis: how good interferon turns bad. Clin Immunol 2007, 123:121-128. 10.1016/j.clim.2006.09.016, 1930161, 17112786.
65. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, Barrat FJ, Coffman RL, Staprans SI, Feinberg MB. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008, 14:1077-1087. 10.1038/nm.1871, 18806803.
66. Taghavi N, Samuel CE. Protein kinase PKR catalytic activity is required for the PKR-dependent activation of mitogen-activated protein kinases and amplification of interferon beta induction following virus infection. Virology 2012, 427:208-216. 10.1016/j.virol.2012.01.029, 3313008, 22381929.
67. Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR. NF-kappaB activation by double-stranded-RNA-activated protein kinase (PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. Mol Cell Biol 2000, 20:1278-1290. 10.1128/MCB.20.4.1278-1290.2000, 85265, 10648614.
68. Tu YC, Yu CY, Liang JJ, Lin E, Liao CL, Lin YL. Blocking double-stranded RNA-activated protein kinase PKR by Japanese encephalitis virus nonstructural protein 2A. J Virol 2012, 86:10347-10358. 10.1128/JVI.00525-12, 3457255, 22787234.
69. Maitra RK, McMillan NA, Desai S, McSwiggen J, Hovanessian AG, Sen G, Williams BR, Silverman RH. HIV-1 TAR RNA has an intrinsic ability to activate interferon-inducible enzymes. Virology 1994, 204:823-827. 10.1006/viro.1994.1601, 7524241.
70. Mouland AJ, Heveker N, Gatignol A. Virus-cell interactions. Encyclopedia of molecular cell biology and molecular medicine 2005, 423-484. Weinheim, Germany: Wiley-VCH Verlag, Meyers RA, 2.
71. Phuphuakrat A, Kraiwong R, Boonarkart C, Lauhakirti D, Lee TH, Auewarakul P. Double-stranded RNA adenosine deaminases enhance expression of human immunodeficiency virus type 1 proteins. J Virol 2008, 82:10864-10872. 10.1128/JVI.00238-08, 2573204, 18753201.
72. Endo-Munoz L, Warby T, Harrich D, McMillan NA. Phosphorylation of HIV Tat by PKR increases interaction with TAR RNA and enhances transcription. Virol J 2005, 2:17. 10.1186/1743-422X-2-17, 556014, 15737233.
73. Redfern AD, Colley SM, Beveridge DJ, Ikeda N, Epis MR, Li X, Foulds CE, Stuart LM, Barker A, Russell VJ, Ramsay K, Kobelke SJ, Li X, Hatchell EC, Payne C, Giles KM, Messineo A, Gatignol A, Lanz RB, O'Malley BW, Leedman PJ. RNA-induced silencing complex (RISC) proteins PACT, TRBP, and dicer are SRA binding nuclear receptor coregulators. Proc Natl Acad Sci USA 2013, 110:6536-6541. 10.1073/pnas.1301620110, 23550157.
74. Kok KH, Ng MH, Ching YP, Jin DY. Human TRBP and PACT directly interact with each other and associate with dicer to facilitate the production of small interfering RNA. J Biol Chem 2007, 282:17649-17657. 10.1074/jbc.M611768200, 17452327.
75. Kok KH, Lui PY, Ng MH, Siu KL, Au SW, Jin DY. The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe 2011, 9:299-309. 10.1016/j.chom.2011.03.007, 21501829.
76. Chatel-Chaix L, Clément J-F, Martel C, Bériault V, Gatignol A, DesGroseillers L, Mouland AJ. Identification of Staufen in the human immunodeficiency virus type 1 Gag ribonucleoprotein complex and a role in generating infectious viral particles. Mol Cell Biol 2004, 24:2637-2648. 10.1128/MCB.24.7.2637-2648.2004, 371130, 15024055.
77. Abrahamyan LG, Chatel-Chaix L, Ajamian L, Milev MP, Monette A, Clément J-F, Song R, Lehmann M, DesGroseillers L, Laughrea M, Boccaccio G, Mouland AJ. Novel Staufen1 ribonucleoproteins prevent formation of stress granules but favour encapsidation of HIV-1 genomic RNA. J Cell Sci 2010, 123:369-383. 10.1242/jcs.055897, 20053637.
78. Chatel-Chaix L, Abrahamyan L, Frechina C, Mouland AJ, DesGroseillers L. The host protein Staufen1 participates in human immunodeficiency virus type 1 assembly in live cells by influencing pr55Gag multimerization. J Virol 2007, 81:6216-6230. 10.1128/JVI.00284-07, 1900086, 17428849.
79. Chatel-Chaix L, Boulay K, Mouland AJ, Desgroseillers L. The host protein Staufen1 interacts with the Pr55Gag zinc fingers and regulates HIV-1 assembly via its N-terminus. Retrovirol 2008, 5:41.
80. Daniels SM, Melendez-Peña CE, Scarborough RJ, Daher A, Christensen HS, El Far M, Purcell DF, Lainé S, Gatignol A. Characterization of the TRBP domain required for dicer interaction and function in RNA interference. BMC Mol Biol 2009, 10:38. 10.1186/1471-2199-10-38, 2685382, 19422693.
81. Lainé S, Scarborough RJ, Lévesque D, Didierlaurent L, Soye KJ, Mougel M, Perreault JP, Gatignol A. In vitro and in vivo cleavage of HIV-1 RNA by new SOFA-HDV ribozymes and their potential to inhibit viral replication. RNA Biol 2011, 8:343-353. 10.4161/rna.8.2.15200, 21422817.
82. Wickham L, Duchaine T, Luo M, Nabi IR, DesGroseillers L. Mammalian staufen is a double-stranded-RNA- and tubulin-binding protein which localizes to the rough endoplasmic reticulum. Mol Cell Biol 1999, 19:2220-2230. 84015, 10022909.
83. Scarborough RJ, Lévesque MV, Perreault J-P, Gatignol A. Design and evaluation of clinically relevant SOFA-HDV Ribozymes targeting HIV RNA. Methods in molecular biology USA: Humana Press, in press.
84. Battisti PL, Daher A, Bannwarth S, Voortman J, Peden KW, Hiscott J, Mouland AJ, Benarous R, Gatignol A. Additive activity between the trans-activation response RNA-binding protein, TRBP2, and cyclin T1 on HIV type 1 expression and viral production in murine cells. AIDS Res Hum Retrovi 2003, 19:767-778.
85. Laurent AG, Krust B, Galabru J, Svab J, Hovanessian AG. Monoclonal antibodies to an interferon-induced Mr 68,000 protein and their use for the detection of double-stranded RNA-dependent protein kinase in human cells. Proc Natl Acad Sci USA 1985, 82:4341-4345. 10.1073/pnas.82.13.4341, 390409, 3859866.
86. Bounou S, Leclerc JE, Tremblay MJ. Presence of host ICAM-1 in laboratory and clinical strains of human immunodeficiency virus type 1 increases virus infectivity and CD4(+)-T-cell depletion in human lymphoid tissue, a major site of replication in vivo. J Virol 2002, 76:1004-1014. 10.1128/JVI.76.3.1004-1014.2002, 135853, 11773376.